Developing New Treatments with a Proprietary Cell-Based Therapy Platform | Lineage Cell Therapeutics, Inc. (NYSE American: LCTX)

Lineage Cell Therapeutics
Published on: October 27, 2020
Author: Editor

Brian Culley, CEO, and Brandi Roberts, CFO of Lineage Cell Therapeutics, Inc. (NYSE AMERICAN: LCTX), a leading publicly traded cell therapy and transplant company with in-house manufacturing and 3 clinical programs with billion dollar opportunities, will be presenting to investors on November 5, 2020 at the GCFF Virtual Conference – Diversified Investing Strategies

The Company’s clinical-stage programs are based on one of the largest and most comprehensive patent estates in cell therapy:

  • OpRegen, an RPE transplant therapy in Phase 1/2a development for the treatment of dry-AMD.  Positive clinical results reported in first 18 enrolled patients; 3 patients left to enroll.  Encouraging findings have been seen across multiple assessments, including reduced growth of geographic atrophy, improved visual acuity, improved reading speed, stable engraftment of cells, and in one patient to date, the first known report of retinal tissue restoration. Next clinical data update planned for 2020 AAO Meeting.   

  • OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries with Orphan and RMAT designations.  96% of 22 subjects treated reported improved motor function from the Phase 1/2a study for treatment of acute SCI; 1/3 of these patients saw improvements of 2 or more motor function levels. Program focus in 2020 is completing manufacturing and delivery enhancements to support a late stage clinical trial.

  • VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Phase 1 for NSCLC conducted and paid for by Cancer Research UK. Program brought in-house in May 2020 based on positive immunogenicity data in first four patients. Recently reported remarkably potent induction of immune responses observed in the ongoing Phase 1 study, with peripheral antigen-specific immunogenicity above 3% observed at multiple timepoints.

Brian and Brandi are part of a dynamic management team that is committed to making the promise of cell therapy a reality; they have done a lot of work over the last 2 years to set Lineage up as a leading cell therapy company.  We hope you are able to join our presentation on November 5th!

LineageRegister for free now 

Corporate Speaker

Brian M. Culley, B.S., M.B.A., CEO

Mr. Culley joined Lineage as CEO in September 2018.  Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.


Biotechnology GCFF Life Science